Clinical Sarcoma Research最新文献

{"title":"Osteosarcoma follow-up: chest X-ray or computed tomography?","authors":"Anna Paioli,&nbsp;Michele Rocca,&nbsp;Luca Cevolani,&nbsp;Eugenio Rimondi,&nbsp;Daniel Vanel,&nbsp;Emanuela Palmerini,&nbsp;Marilena Cesari,&nbsp;Alessandra Longhi,&nbsp;Abate Massimo Eraldo,&nbsp;Emanuela Marchesi,&nbsp;Piero Picci,&nbsp;Stefano Ferrari","doi":"10.1186/s13569-017-0067-5","DOIUrl":"https://doi.org/10.1186/s13569-017-0067-5","url":null,"abstract":"<p><strong>Background: </strong>In patients with relapsed osteosarcoma, the surgical excision of all metastases, defined as second complete remission (CR-2), is the factor that mainly influences post-relapse survival (PRS). Currently a validated follow-up policy for osteosarcoma is not available, both chest X-ray and computed tomography (CT) are suggested for lung surveillance. The purpose of this study is to evaluate whether the type of imaging technique used for chest surveillance, chest X-ray or CT, influenced the rate of CR-2 and prognosis in patients with recurrent osteosarcoma.</p><p><strong>Methods: </strong>Patients up to 40 years with extremity osteosarcoma enrolled in consecutive clinical trials and treated at the Rizzoli Institute from 1986 to 2009 were identified. Only patients who had lung metastases alone as first pattern of recurrence were considered for the analysis. The rate of CR-2, overall survival (OS) and PRS were the end-points of the study.</p><p><strong>Results: </strong>The median follow-up was 47 months (1-300), 215 patients were eligible. Lung metastases were detected by chest X-ray in 100 (47%) patients, by CT in 112 (52%) and by symptoms in 3 (1%). CR-2 rate was 60% for patients followed by X-rays and 88% for those followed by CT (p < .0001). 5-year PRS was 30% (95% CI 21-39) in the X-ray group and 49% (95% CI 39-59) in the CT group (p = .0004). 5-year OS was 35% (95% CI 26-44) in the X-ray group and 60% (95% CI 51-70) in the CT group (p = .004).</p><p><strong>Conclusions: </strong>A follow-up strategy with chest CT leads to a higher rate of CR-2 and significantly improves PRS and OS in osteosarcoma, compared to chest X-ray.</p>","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"7 ","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2017-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-017-0067-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34757320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study","authors":"M. C. Verboom, J. Ouwerkerk, N. Steeghs, J. Lutjeboer, J. Martijn Kerst, W. V. D. van der Graaf, A. Reyners, S. Sleijfer, H. Gelderblom","doi":"10.1186/s13569-017-0066-6","DOIUrl":"https://doi.org/10.1186/s13569-017-0066-6","url":null,"abstract":"","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-017-0066-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48402129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy in the management of gist: state of the art and new potential scenarios","authors":"L. Gatto, M. Nannini, M. Saponara, V. Scioscio, G. Beltramo, G. Frezza, Giorgio Ercolani, A. D. Pinna, A. Astolfi, M. Urbini, G. Brandi, G. Biasco, M. Pantaleo","doi":"10.1186/s13569-016-0065-z","DOIUrl":"https://doi.org/10.1186/s13569-016-0065-z","url":null,"abstract":"","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-016-0065-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43593480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic meningioma presenting as a malignant soft tissue tumour","authors":"C. McCarthy, M. Hofer, M. Vlychou, R. Khundkar, P. Critchley, S. Cudlip, O. Ansorge, N. Athanasou","doi":"10.1186/s13569-016-0063-1","DOIUrl":"https://doi.org/10.1186/s13569-016-0063-1","url":null,"abstract":"","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-016-0063-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65853335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to anti-PD1 therapy with nivolumab in metastatic sarcomas","authors":"L. Paoluzzi, A. Cacavio, M. Ghesani, A. Karambelkar, A. Rapkiewicz, J. Weber, Gerald Rosen","doi":"10.1186/s13569-016-0064-0","DOIUrl":"https://doi.org/10.1186/s13569-016-0064-0","url":null,"abstract":"","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-016-0064-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65853408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour","authors":"Ivar Hompland, Ø. Bruland, Kumari Ubhayasekhera, J. Bergquist, K. Boye","doi":"10.1186/s13569-016-0062-2","DOIUrl":"https://doi.org/10.1186/s13569-016-0062-2","url":null,"abstract":"","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-016-0062-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65853320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pazopanib: a novel treatment option for aggressive fibromatosis","authors":"G. Bulut, Anil Ozluk, A. Erdoğan, R. Uslu, N. Elmas, B. Karaca","doi":"10.1186/s13569-016-0061-3","DOIUrl":"https://doi.org/10.1186/s13569-016-0061-3","url":null,"abstract":"","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-016-0061-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65853713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UK guidelines for the management of soft tissue sarcomas.","authors":"Adam Dangoor, Beatrice Seddon, Craig Gerrand, Robert Grimer, Jeremy Whelan, Ian Judson","doi":"10.1186/s13569-016-0060-4","DOIUrl":"10.1186/s13569-016-0060-4","url":null,"abstract":"<p><p>Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues, and can occur almost anywhere in the body. Their rarity, and the heterogeneity of subtype and location means that developing evidence-based guidelines is complicated by the limitations of the data available. However, this makes it more important that STS are managed by teams, expert in such cases, to ensure consistent and optimal treatment, as well as recruitment to clinical trials, and the ongoing accumulation of further data and knowledge. The development of appropriate guidance, by an experienced panel referring to the evidence available, is therefore a useful foundation on which to build progress in the field. These guidelines are an update of the previous version published in 2010 (Grimer et al. in Sarcoma 2010:506182, 2010). The original guidelines were drawn up following a consensus meeting of UK sarcoma specialists convened under the auspices of the British Sarcoma Group (BSG) and were intended to provide a framework for the multidisciplinary care of patients with soft tissue sarcomas. This current version has been updated and amended with reference to other European and US guidance. There are specific recommendations for the management of selected subtypes of disease including retroperitoneal and uterine sarcomas, as well as aggressive fibromatosis (desmoid tumours) and other borderline tumours commonly managed by sarcoma services. An important aim in sarcoma management is early diagnosis and prompt referral. In the UK, any patient with a suspected soft tissue sarcoma should be referred to one of the specialist regional soft tissues sarcoma services, to be managed by a specialist sarcoma multidisciplinary team. Once the diagnosis has been confirmed using appropriate imaging, plus a biopsy, the main modality of management is usually surgical excision performed by a specialist surgeon. In tumours at higher risk of recurrence or metastasis pre- or post-operative radiotherapy should be considered. Systemic anti-cancer therapy (SACT) may be utilized in some cases where the histological subtype is considered more sensitive to systemic treatment. Regular follow-up is recommended to assess local control, development of metastatic disease, and any late-effects of treatment. For local recurrence, and more rarely in selected cases of metastatic disease, surgical resection would be considered. Treatment for metastases may include radiotherapy, or systemic therapy guided by the sarcoma subtype. In some cases, symptom control and palliative care support alone will be appropriate.</p>","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"6 1","pages":"20"},"PeriodicalIF":0.0,"publicationDate":"2016-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-016-0060-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65853679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series","authors":"A. Lipplaa, S. Dijkstra, H. Gelderblom","doi":"10.1186/s13569-016-0059-x","DOIUrl":"https://doi.org/10.1186/s13569-016-0059-x","url":null,"abstract":"","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-016-0059-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65853625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome and the effect of age and socioeconomic status in 1318 patients with synovial sarcoma in the English National Cancer Registry: 1985–2009","authors":"B. Brennan, C. Stiller, R. Grimer, N. Dennis, J. Broggio, M. Francis","doi":"10.1186/s13569-016-0058-y","DOIUrl":"https://doi.org/10.1186/s13569-016-0058-y","url":null,"abstract":"","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-016-0058-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65853309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}